Pfizer 2022 Near-Term Launches High-Value Pipeline

Pfizer's December 2022 investor presentation covering near-term product launches including Nurtec, RSV vaccines, etrasimod, ritlecitinib, and elranatamab, alongside high-value pipeline candidates in immunology and mRNA vaccines. The event details regulatory timelines, clinical development status, and commercial strategies for key therapeutic areas.